ArticleCell death & disease2026
UBE2M-mediated neddylation modification stabilizes VEGFR2 to delay pulmonary vascular endothelial cell senescence.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Pulmonary aging is characterized by progressive structural and functional decline. Neddylation is recognized as a crucial mechanism for maintaining cellular homeostasis; however, its function in pulmonary aging has not been fully elucidated. In this study, we found that the core neddylation E2 enzyme UBE2M was downregulated in aged lung tissues. Ube2m knockdown mice exhibited premature pulmonary aging, including vascular degeneration and structural disruption. Notably, in the lungs of knockout mice, although VEGF expression-primarily secreted by epithelial cells-remained unchanged, the protein level and phosphorylation of its receptor VEGFR2 on endothelial cells were significantly reduced. Mechanistic investigation confirmed that UBE2M directly regulates VEGFR2 stability in pulmonary endothelial cells via neddylation. In a doxorubicin-induced endothelial cell senescence model, UBE2M downregulation was accompanied by impaired VEGFR2 signaling, whereas UBE2M reconstitution partially alleviated cellular senescence. In elastase-induced emphysema mouse models and in lung tissues from COPD patients, both UBE2M and VEGFR2 levels were markedly reduced, and Ube2m deficiency exacerbated lung injury. In conclusion, this study demonstrates that UBE2M delays pulmonary aging by stabilizing VEGFR2 through neddylation, suggesting its potential as a therapeutic target for age-related pulmonary diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.